Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1855-1861

  Miyawaki, Shuichi ^a   Hatsumi, Nahoko ^b   Tamaki, Toshiharu ^c   Naoe, Tomoki ^d   Ozawa, Keiya ^e   Kitamura, Kunio ^f   Karasuno, Takahiro ^g   Mitani, Kinuko ^h   Kodera, Yoshihisa ⁱ   Yamagami, Tamotsu ^j   Koga, Daisuke ^k  

^a Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c Rinku General Medical Center   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f Ichinomiya Municipal Hospital   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h DOKKYO MEDICAL UNIVERSITY   (Japan)

ⁱ JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^j MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^k OTSUKA PHARMACEUTICAL CO LTD   (Japan)

more..

Author keywords

AML; minimal residual disease; prognosis; real time RT PCR; WT1

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ENOCITABINE; IDARUBICIN; MESSENGER RNA; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; TUMOR GENE; TUMOR SUPPRESSOR GENE; WILMS TUMOR GENE 1;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 77957726845     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.507829     Document Type: Article

References (20)

1. Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study ofindividualized induction therapy with or without vincristine, and of maintenance- intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 1993;71: 3888-3895.
2. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combina-tion induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;14:204-213.
3. Miyawaki S, Tanimoto M, Kobayashi T, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999;70:97-104.
4. Büchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytar-abine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21:4496-4504.
5. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytar-abine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years ofage: Cancer and Leukemia Group B Study 9222. Blood 2005;105:3420-3427.
6. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988;6:583-587.
7. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
8. Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 2004; 125: 590-600.
9. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19:1416-1423.
10. Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24:1507-1515.
11. Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008;141:782-791.
12. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leuke-miaNet study. J Clin Oncol 2009;27:5195-5201.
13. Miyawaki S, Emi N, Mitani K, et al. Clinical course ofthe disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institu-tions in Japan. Rinsho Ketsueki 2005;46:1279-1287.
14. Miyawaki S, Ohtake S, Fujisawa S, et al. Long-term follow-up of the randomized JALSG AML 201 study comparing high dose Ara-C therapy with conventional consolidation therapy in adult acute myeloid leukemia (AML). Blood 2008;112(Suppl. 1): Abstract 135.
15. Osumi K, Fukui T, Kiyoi H, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 2002;43:2291-2299.
16. Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. The detection of WT-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:91-96.
17. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prog-nostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-1894.
18. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measure-ment of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008;93:921-924.
19. Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring ofminimal residual disease in acute leukemia. Leuk Lymphoma 2009;50:1326-1332.
20. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756.